Korean J Transplant.  2023 Nov;37(Suppl 1):S202. 10.4285/ATW2023.F-7910.

Comparison of lung transplant patients as a cause of COVID-19 and non-COVID-19

• Lee S
• Lee S
• Min K
• Jeong H
• Park J
• Park S

• KMID: 2551822
• DOI: http://doi.org/10.4285/ATW2023.F-7910

Abstract

Background
As coronavirus disease 2019 (COVID-19) infection spread from 2020, lung disease patients due to COVID-19 infection occurred, and lung transplantation was performed as a treatment. We want to compare the data of the two groups, such as general characteristics and survival rates, of patients who received lung transplantation as a cause of COVID-19 and non-COVID-19, to identify differences.
Methods
Patients who received lung transplantation from January 2020 to December 2022 at Seoul National University Hospital were targeted. Data were collected through medical records before and after surgery by classifying patients with lung disease due to COVID-19 and non-COVID-19.
Results
Patients had a mean age of 54±17.0 years, 51% (n=26) were male, cause of COVID-19 11.8% (n=6), mean Sequential Organ Failure Assessment (SOFA) score of 6.4±4.0, mean Acute Physiology and Chronic Health Evaluation II score of 16.7±7.67 and admission period were 58.5±54.7 days. Forty patients (78.4%) had a comorbidity, the 1-year survival rate after lung transplantation was 80.4%. We analyzed lung transplantation as a cause of COVID-19 vs. non-COVID-19. In the univariate logistic model comorbidities (odds ratio [OR], 10.857; P=0.013) SOFA score pre-liver transplantation (LT; OR, 1.562; P=0.014.) admission period (OR, 1.015; P=0.037) were independently associated factors. SOFA score pre-LT (OR, 2.060; P=0.036) was only significant in multivariate logistic model.
Conclusions
The 1-year survival rate of lung transplant patients as a cause of COVID-19 (66.6%) was lower than the 1-year survival rate of non-COVID-19 (82%). It was similar to the 1-year survival rate of the National Institute of Organ Tissue and Blood Management (66.5%). Lung transplantation patients as a cause of COVID-19 had lower comorbidities than non-COVID-19, but had a higher SOFA score (pre-LT) and mortality. Lung transplantation patients as a cause of COVID-19, are expected to disease progress more rapidly before transplant than non-COVID-19, resulting in poor prognosis.